

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Not for submission under 37 CFR 1.99)

Application Number		10562246
Filing Date		2003-06-24
First Named Inventor	Stephen John Martin Skinner	
Art Unit		
Examiner Name		
Attorney Docket Number	36697.16	

U.S. PATENTS[Remove](#)

Examiner Initial*	Cite No	Patent Number	Kind Code ¹	Issue Date	Name of Patentee or Applicant of cited Document	Pages, Columns, Lines where Relevant Passages or Relevant Figures Appear
	1	4850993		1989-07-25	Champion et al.	
	2	5389535		1995-02-14	Bisector et al.	
	3	5550050		1996-08-27	Holland et al	
	4	5561108		1996-10-01	Tsay et al.	
	5	5573528		1996-11-12	Aebischer et al.	
	6	5762926		1998-06-06	Gage et al.	
	7	5853385		1998-12-19	Emerich et al.	
	8	5869463		1999-02-09	Major et al.	

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Not for submission under 37 CFR 1.99)

Application Number		10562246
Filing Date		2003-06-24
First Named Inventor	Stephen John Martin Skinner	
Art Unit		
Examiner Name		
Attorney Docket Number	36697.16	

9	5871767		1999-02-16	Dionne et al.	
10	5888705		1999-03-30	Rubin et al.	
11	5898066		1999-08-27	Benowitz et al.	
12	5968829		1999-10-19	Carpenter	
13	6090400		2000-07-18	Elliott	
14	6146653		2000-11-14	Elliott	
15	6225310		2001-05-01	Nielsen	
16	6432710		2002-08-13	Boss	

If you wish to add additional U.S. Patent citation information please click the Add button.

Add

U.S. PATENT APPLICATION PUBLICATIONS

Remove

Examiner Initial*	Cite No	Publication Number	Kind Code ¹	Publication Date	Name of Patentee or Applicant of cited Document	Pages, Columns, Lines where Relevant Passages or Relevant Figures Appear
	1	20030044391		2003-03-06	Elliott et al.	

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Not for submission under 37 CFR 1.99)

Application Number		10562246
Filing Date		2003-06-24
First Named Inventor	Stephen John Martin Skinner	
Art Unit		
Examiner Name		
Attorney Docket Number	36697.16	

2	20040014212		2004-01-22	Elliott et al.	
3	20040033216		2004-02-19	Elliott et al.	
4	20040213768		2004-10-28	Elliott et al.	
5	20050106128		2005-05-19	Elliott et al.	
6	20050265977		2005-12-01	Elliott et al.	

If you wish to add additional U.S. Published Application citation information please click the Add button.

FOREIGN PATENT DOCUMENTS

Examiner Initial*	Cite No	Foreign Document Number ³	Country Code ² j	Kind Code ⁴	Publication Date	Name of Patentee or Applicant of cited Document	Pages, Columns, Lines where Relevant Passages or Relevant Figures Appear	T ⁵
	1	96/40178	WO		1996-12-19	Research Corporation Technologies		<input type="checkbox"/>
	2	99/36565	WO		1999-07-22	Human Genome Sciences, Inc.		<input type="checkbox"/>
	3	99/49734	WO		1999-10-07	Emory University		<input type="checkbox"/>
	4	99/56770	WO		1999-11-11	Chang		<input type="checkbox"/>

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Not for submission under 37 CFR 1.99)

Application Number		10562246
Filing Date		2003-06-24
First Named Inventor	Stephen John Martin Skinner	
Art Unit		
Examiner Name		
Attorney Docket Number		36697.16

5	00/66188	WO	A2	2000-11-09	Diatranz Limited		<input type="checkbox"/>
6	00/66188	WO	A3	2007-01-16	Diatranz Limited		<input type="checkbox"/>
7	01/52871	WO			Diatranz Limited		<input type="checkbox"/>
8	02/32437	WO			Diatranz Limited		<input type="checkbox"/>
9	03/039566	WO	A2		Elliott et al.		<input type="checkbox"/>
10	03/039566	WO	A3		Elliott et al.		<input type="checkbox"/>
11	81864/98	AU			Diatranz Limited		<input type="checkbox"/>
12	2216055	CA			McGill University		<input type="checkbox"/>
13	250834	NZ			Elliott		<input type="checkbox"/>
14	502473	NZ			Diatranz Limited		<input type="checkbox"/>
15	507616	NZ			Elliott		<input type="checkbox"/>

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Not for submission under 37 CFR 1.99)

Application Number	10562246
Filing Date	2003-06-24
First Named Inventor	Stephen John Martin Skinner
Art Unit	
Examiner Name	
Attorney Docket Number	36697.16

16	515310	NZ			Elliott et al.		<input type="checkbox"/>
----	--------	----	--	--	----------------	--	--------------------------

If you wish to add additional Foreign Patent Document citation information please click the Add button [Add](#)

NON-PATENT LITERATURE DOCUMENTS

[Remove](#)

Examiner Initials*	Cite No	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, pages(s), volume-issue number(s), publisher, city and/or country where published.	T5
	1	BASTA et al., "Xenotransplantation of Microencapsulated Neonatal Procline Islets (NIP) in Diabetic Recipients: Pre-clinical Trials," ACTA Diabetologica, 37, No. 3, pg. 145, September 2000.	<input type="checkbox"/>
	2	BEAL et al., "Differential Sparing of Somatostatin-Neuropeptide Y and Cholinergic Neurons following Striatal Excitotoxin Lesions," Synapse, 3(1):38-47, 1989.	<input type="checkbox"/>
	3	BORLONGAN et al. "Locomotor and Passive Avoidance Deficits Following Occlusion of the Middle Cerebral Artery," Physiology & Behavior, 58:909-17, 1995.	<input type="checkbox"/>
	4	BORLONGAN et al., "Elevated Body Swing Test: A New Behavioral Parameter for Rats with 6-Hydroxydopamine-Induced Hemiparkinsonism," Neurosci., 15:5372-8, 1995.	<input type="checkbox"/>
	5	BORLONGAN et al., "Striatal Dopamine-Mediated Motor Behavior is Altered Following Occlusion of the Middle Cerebral Artery," Pharmacology Biochemistry and Behavior, 52:225-9, 1995.	<input type="checkbox"/>
	6	BORLONGAN et al. "Intercerebral Transplantation of Porcine Choroids Plexus Provides Structural and Functional Neuroprotection in a Rodent Model Of Stroke," Stroke, 35(9):2206-10, 2004.	<input type="checkbox"/>
	7	BRANDHORST et al., "Significant Progress in Porcine Islet Mass Isolating Utilizing Liberase HL for Enzymatic Low Temperature Pancreas Digestion," Transplantation, 68(3):355-361, August 1999.	<input type="checkbox"/>
	8	CALAFIORE et al., "Effects of Alginate/Polyaminoacidic Coherent Microcapsule Transplantation in Adult Pigs," Transplant. Proc., 4 2126-2167, 1997.	<input type="checkbox"/>

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Not for submission under 37 CFR 1.99)

Application Number	10562246
Filing Date	2003-06-24
First Named Inventor	Stephen John Martin Skinner
Art Unit	
Examiner Name	
Attorney Docket Number	36697.16

9	CALAFIORE, "Actual Perspectives in Biohybrid Artificial Pancreas for the Therapy of Type 1, Insulin Dependent Diabetes Mellitus," Diabetes Metab. Rev., 14(4):315-324, December 1998.	<input type="checkbox"/>
10	CALAFIORE et al., "Transplantation of Pancreatic Islets Contained in Minimal Volume Microcapsules in Diabetic High Mammalian," Ann. N.Y. Acad. Sci., 875:219-232, 1999.	<input type="checkbox"/>
11	CAVANAGH et al., "Improved Pig Islet Yield and Post-Culture Recovery Using Liberase PL Purified Enzyme Blend," Transplant. Proc., 30(2): 367, March 1998.	<input type="checkbox"/>
12	CLARK et al., "Islet Cell Culture in Defined Serum-Free Medium," Endocrinology, 126:1895-1903, 1990.	<input type="checkbox"/>
13	ELLIOTT et al., "The Use of Nicotinamide in the Prevention of Type 1 Diabetes," Ann. N.Y. Acad. Sci., 696:333-41, 1993.	<input type="checkbox"/>
14	ELLIOTT et al., "No Evidence of Infection With Porcine Endogenous Retrovirus in Recipients of Encapsulated Porcine Islet Xenografts," Cell Transplantation, 9:895-901, 2000.	<input type="checkbox"/>
15	EMERICH et al., "Implants of Encapsulated Human CNTF-Producing Fibroblasts Prevent Behavioral Deficits and Striatal Degeneration in a Rodent Model of Huntington's Disease," J. Neurosci., 16(16):5168-5181, 1996.	<input type="checkbox"/>
16	FAHN et al., "Double Blind Controlled Trial of Human Embryonic Dopaminergic Tissue Transplants in Advanced Parkinson's Disease: Clinical Outcomes," Neurology, 52 [Suppl 2]:A405, April 1999.	<input type="checkbox"/>
17	FUKUDA et al., "Astrocytes Are More Vulnerable Than Neurons to Cellular Ca ²⁺ Overload Induced By A Mitochondrial Toxin, 3-Nitropropionic Acid," Neurosci., 87(2):497-507, 1998.	<input type="checkbox"/>
18	KALLMANN et al., "Toxicity of Chemically Generated Nitric Oxide Towards Pancreatic Islet Cells Can Be Prevented By Nicotinamide," Life Sciences, 51:671-678, 1992.	<input type="checkbox"/>
19	KITADA MASAOKI et al. "Axonal Regeneration in the Central Nervous System is Enhanced by Ependymal Cell Transplants," Neosci. Research Supplement, 22:S318, 1998. XP000960785 21st Annual Meeting of the Japan Neuroscience Society and the First Joint Meeting of the Japan Neuroscience Society and the Japanese Society for Neurochemistry; Tokyo, Japan; September 21 - 23, 1998. ISSN. 0921-8696.	<input type="checkbox"/>

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Not for submission under 37 CFR 1.99)

Application Number	10562246
Filing Date	2003-06-24
First Named Inventor	Stephen John Martin Skinner
Art Unit	
Examiner Name	
Attorney Docket Number	36697.16

20	KOPYOV et al., "Safety of Intrastriatal Neurotransplantation for Huntington's Disease Patients," <i>Experimental Neurology</i> , 149:97-106, 1998.	<input type="checkbox"/>
21	KORBUTT et al., "Cotransplantation of Allogeneic Islets with Allogeneic Testicular Cell Aggregates Allows Long-Term Graft Survival Without Systemic Immunosuppression," <i>Diabetes</i> , 46: 317-322, Feb. 1997.	<input type="checkbox"/>
22	KORDOWER et al., "Cellular Delivery of Trophic Factors for the Treatment of Huntington's Disease: Is Neuroprotection Possible?," <i>Experimental Neurology</i> , 159:4-20, 1999.	<input type="checkbox"/>
23	KREWSON et al., "Distribution of Nerve Growth Factor Following Direct Delivery to Brain Interstitium," <i>Brain Res.</i> , 680 (1-2):196-206, 1995.	<input type="checkbox"/>
24	LANZA et al., "Biohybrid Artificial Pancreas: Long -Term Functioning of Discordant Islet Xenografts in Streptozotocin Diabetic Rats," <i>Transplantation</i> , 56:1067-1072, 1993.	<input type="checkbox"/>
25	LINDVALL, et al., "Histochemical, Ultrastructural and Functional Evidence for a Neurogenic Control of Cerebrospinal Fluid Production From the Choroid Plexus," <i>Acta Physiologica Scand. Suppl.</i> , 452:77-86, 1977.	<input type="checkbox"/>
26	LONDON et al., "A Simple Method for the Release of Islets by Controlled Collagenase Digestion of the Human Pancreas," <i>Transplantation</i> , 49(6):1109-1113, June 1990.	<input type="checkbox"/>
27	LUCA et al., "Sertoli Cell-Induced Reversal of Adult Rat Pancreatic Islet B-Cells Into Fetal-Like Status: Potential Implications for Islet Transplantation into Type 1 Diabetes Mellitus," <i>J. Invest. Medicine</i> , 48(6):441-448, Nov 2000.	<input type="checkbox"/>
28	MAKI et al., "Porcine Islets Xenotransplantation Utilizing a Vascularized Bioartificial Pancreas," <i>Ann. of Transplantation</i> , 2(3):69-71, 1997.	<input type="checkbox"/>
29	MARTI et al., "Systemic Hypoxia Changes the Organ-Specific Distribution of Vascular Endothelial Growth Factor and its Receptors," <i>Proc. Natl. Acad. Sci.</i> , 95:15809-15814, 1998.	<input type="checkbox"/>
30	MEHLER et al., "Progenitor Cell Biology Implications for Neural Regeneration," <i>Arch. Neurol.</i> 56:780-784, 1999.	<input type="checkbox"/>

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Not for submission under 37 CFR 1.99)

Application Number	10562246
Filing Date	2003-06-24
First Named Inventor	Stephen John Martin Skinner
Art Unit	
Examiner Name	
Attorney Docket Number	36697.16

31	NGO et al , "Computational Complexity, Protein Structure Prediction, and the Levinthal Paradox," The Protein Folding Problem and Tertiary Structure Prediction, Birkhauser Boston: Boston, MA, 1994.	<input type="checkbox"/>
32	ORIVE et al., "Cell Encapsulation: Promise and Progress," Nature Medicine, 9(1):104-107, 2003.	<input type="checkbox"/>
33	PARDRIDGE, "Peptide Drug Delivery To The Brain," 1991, 114-122; 305; 307, New York: Raven Press.	<input type="checkbox"/>
34	PAXINOS et al., "The Rat Brain in Stereotaxic Coordinates," Academic Press, New York, 1986.	<input type="checkbox"/>
35	PU et al., "Effect of Lignocaine in Myocardial Contusion: An Experiment on Rabbit Isolated Heart," Brit. J. Pharmacol. 118:1072-1078, 1996.	<input type="checkbox"/>
36	RAO et al., "Choroid Plexus Epithelial Expression of MDR1 P Glycoprotein And Multidrug Resistance-Associated Protein Contribute to the Blood-Cerebrospinal-Fluid Drug-Permeability Barrier," Proc. Natl. Acad. Sci., 96:3900-3905, 1999.	<input type="checkbox"/>
37	RAYAT et al., "Expression of Gal (1,3) Gal on Neonatal Porcine Islet B-Cells and Susceptibility to Human Antibody/ Complement Lysis," Diabetes, 47:1406-1411, September 1998.	<input type="checkbox"/>
38	RAYAT et al., "Potential Application of Neonatal Porcine Islets as Treatment for Type 1 Diabetes: A Review," Ann. N.Y. Acad. Sci., 875 175-188, 1999.	<input type="checkbox"/>
39	RUDINGER, "Characteristics of the Amino Acids as Components of a Peptide Hormone Sequence," University Park Press: Baltimore, MD, pp. 1-7, 1976.	<input type="checkbox"/>
40	SALZBERG-BRENHOUSE et al., "Inhibitors of Cyclooxygenase-2, but Not Cyclooxygenase-1 Provide Structural and Functional Protection against Quinolinic Acid-Induced Neurodegeneration," J. of Pharmacology and Experimental Therapeutics, 306 218-228, 2003.	<input type="checkbox"/>
41	SAURA et al, "Neuroprotective Effects of Gly-Pro-Glu, the N-terminal Tripeptide of IGF-1, in the Hippocampus in vitro," Neuroendocrinol., 10(1):161-164, 1999.	<input type="checkbox"/>

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Not for submission under 37 CFR 1.99)

Application Number	10562246
Filing Date	2003-06-24
First Named Inventor	Stephen John Martin Skinner
Art Unit	
Examiner Name	
Attorney Docket Number	36697.16

42	SEGAL, "The Choroid Plexuses and the Barriers Between the Blood and the Cerebrospinal Fluid," Cell Mol Neurobio., 20(2):183-196, 2000.	<input type="checkbox"/>
43	SELAWRY et al., "Sertoli Cell-Enriched Fractions in Successful Islet Cell Transplantation," Cell Transplantation, 2:123-129, 1993.	<input type="checkbox"/>

If you wish to add additional non-patent literature document citation information please click the Add button

EXAMINER SIGNATURE

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ See Kind Codes of USPTO Patent Documents at www.USPTO.GOV or MPEP 901.04. ² Enter office that issued the document, by the two-letter code (WIPO Standard ST.3). ³ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁴ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁵ Applicant is to place a check mark here if English language translation is attached.

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Not for submission under 37 CFR 1.99)

Application Number	10562246
Filing Date	2003-06-24
First Named Inventor	Stephen John Martin Skinner
Art Unit	
Examiner Name	
Attorney Docket Number	36697.16

CERTIFICATION STATEMENT

Please see 37 CFR 1.97 and 1.98 to make the appropriate selection(s):

☐ That each item of information contained in the information disclosure statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the information disclosure statement. See 37 CFR 1.97(e)(1).

OR

☐ That no item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing the certification after making reasonable inquiry, no item of information contained in the information disclosure statement was known to any individual designated in 37 CFR 1.56(c) more than three months prior to the filing of the information disclosure statement. See 37 CFR 1.97(e)(2).

- ☐ See attached certification statement.
- ☐ Fee set forth in 37 CFR 1.17 (p) has been submitted herewith.
- ☒ None

SIGNATURE

A signature of the applicant or representative is required in accordance with CFR 1.33, 10.18. Please see CFR 1.4(d) for the form of the signature.

Signature	/Mark D. Moore/	Date (YYYY-MM-DD)	2007-01-17
Name/Print	Mark D. Moore, Ph.D.	Registration Number	42,903

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 1 hour to complete, including gathering, preparing and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. **DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

Privacy Act Statement

The Privacy Act of 1974 (P.L. 93-579) requires that you be given certain information in connection with your submission of the attached form related to a patent application or patent. Accordingly, pursuant to the requirements of the Act, please be advised that: (1) the general authority for the collection of this information is 35 U.S.C. 2(b)(2); (2) furnishing of the information solicited is voluntary; and (3) the principal purpose for which the information is used by the U.S. Patent and Trademark Office is to process and/or examine your submission related to a patent application or patent. If you do not furnish the requested information, the U.S. Patent and Trademark Office may not be able to process and/or examine your submission, which may result in termination of proceedings or abandonment of the application or expiration of the patent.

The information provided by you in this form will be subject to the following routine uses:

1. The information on this form will be treated confidentially to the extent allowed under the Freedom of Information Act (5 U.S.C. 552) and the Privacy Act (5 U.S.C. 552a). Records from this system of records may be disclosed to the Department of Justice to determine whether the Freedom of Information Act requires disclosure of these records.
2. A record from this system of records may be disclosed, as a routine use, in the course of presenting evidence to a court, magistrate, or administrative tribunal, including disclosures to opposing counsel in the course of settlement negotiations.
3. A record in this system of records may be disclosed, as a routine use, to a Member of Congress submitting a request involving an individual, to whom the record pertains, when the individual has requested assistance from the Member with respect to the subject matter of the record.
4. A record in this system of records may be disclosed, as a routine use, to a contractor of the Agency having need for the information in order to perform a contract. Recipients of information shall be required to comply with the requirements of the Privacy Act of 1974, as amended, pursuant to 5 U.S.C. 552a(m).
5. A record related to an International Application filed under the Patent Cooperation Treaty in this system of records may be disclosed, as a routine use, to the International Bureau of the World Intellectual Property Organization, pursuant to the Patent Cooperation Treaty.
6. A record in this system of records may be disclosed, as a routine use, to another federal agency for purposes of National Security review (35 U.S.C. 181) and for review pursuant to the Atomic Energy Act (42 U.S.C. 218(c)).
7. A record from this system of records may be disclosed, as a routine use, to the Administrator, General Services, or his/her designee, during an inspection of records conducted by GSA as part of that agency's responsibility to recommend improvements in records management practices and programs, under authority of 44 U.S.C. 2904 and 2906. Such disclosure shall be made in accordance with the GSA regulations governing inspection of records for this purpose, and any other relevant (i.e., GSA or Commerce) directive. Such disclosure shall not be used to make determinations about individuals.
8. A record from this system of records may be disclosed, as a routine use, to the public after either publication of the application pursuant to 35 U.S.C. 122(b) or issuance of a patent pursuant to 35 U.S.C. 151. Further, a record may be disclosed, subject to the limitations of 37 CFR 1.14, as a routine use, to the public if the record was filed in an application which became abandoned or in which the proceedings were terminated and which application is referenced by either a published application, an application open to public inspections or an issued patent.
9. A record from this system of records may be disclosed, as a routine use, to a Federal, State, or local law enforcement agency, if the USPTO becomes aware of a violation or potential violation of law or regulation.